Articles tagged with Drug Targets
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.
A new study examines cannabis use patterns, motivations, and risk factors among college students at a large public university in the southeastern US. The researchers found that top reasons for cannabis use were relaxation and social pressure, while daily users reported higher quantity of cannabis per day.
Brazilian researchers screened 160 existing drugs and identified six compounds effective against Toxoplasma gondii. Almitrine, a COPD treatment, showed significant reduction in brain parasite load. Further studies are needed to repurpose these drugs for toxoplasmosis treatment.
A real-world study confirms the reliability and effectiveness of the Pooled Cohort Equation (PCE) in assessing cardiovascular risk, regardless of statin use. The PCE performed well across different demographics and retained accuracy with measurement factors outside its original risk profile range.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers found that etripamil nasal spray restored normal heart rhythms within 30 minutes in 54% of patients, making it a potential new option for self-treating paroxysmal supraventricular tachycardia. The study showed the medication to be safe and well-tolerated.
Veterinary researchers used 3D organoids to investigate lung cancer in dogs, finding that canine primary lung cancer organoids faithfully mirrored tumor tissues. The study identified correlations between organoid cell viability and specific target molecules, paving the way for personalized treatment approaches.
Researchers found that adding dendritic cell boosting therapy to radiation and CTLA4 inhibitor combination produced synergistic effect, eliciting tumor regression. This approach resulted in complete or almost complete elimination of targeted tumors.
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
A new Northwestern Medicine study reveals that a dysfunction in the neuron's synapses leads to deficits in dopamine and precedes neurodegeneration in Parkinson's disease. The findings suggest targeting dysfunctional synapses before neurons degenerate may represent a better therapeutic strategy.
A recent study from MIT found that measuring diversity of mutations within a tumor generates more accurate predictions of treatment success than overall mutation count. This discovery could help doctors identify patients who would benefit most from checkpoint blockade inhibitors.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
A new study suggests that transcranial ultrasound stimulation can be used to change specific types of activity within the brain, paving the way for targeted treatments of mental health conditions. The research found that TUS induced significant changes in GABA concentration and altered communication between brain regions.
Researchers found that a combination of AXL and EGFR inhibitors can suppress tumor growth and prevent relapse in patients with certain cancers. The study clarifies the novel regulatory mechanism by which AXL stimulates YAP via the EGFR-LATS1/2 axis.
A randomized trial published in The Lancet Oncology found that condensing prostate beam scanning proton therapy for breast cancer patients can result in similar control of the cancer while sparing surrounding normal tissue. The study demonstrated excellent outcomes, with reduced skin side effects and comparable complication rates.
Researchers at University of Tsukuba found that aripiprazole modulates the mammalian central circadian clock by disrupting synchronization among clock neurons and enhancing responsiveness to light stimuli in mice. This discovery expands the potential clinical usage of aripiprazole as a treatment for circadian rhythm sleep disorders.
Researchers are developing a new treatment for ischemic stroke by targeting the prostaglandin receptor EP2, which could have a wider therapeutic window and improve behavioral outcomes. The potential new treatment has the potential to reduce inflammation and provide protection for neurons after an ischemic stroke.
Chung-Ang University researchers create an electrochemical DNA biosensor that detects HPV-16 and HPV-18 with high specificity, facilitating early diagnosis of cervical cancer. The sensor uses a graphitic nano-onion/MoS2 nanosheet composite to enhance conductivity.
Research found that cold weather slightly increases blood pressure and decreases blood pressure control rates during winter months. Participants' systolic blood pressure increased by up to 1.7 mm Hg in the winter months compared to summer, while blood pressure control rates decreased by up to 5%.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
Mayo Clinic researchers found that cells expressing PD-1 and PD-L1 within a certain distance of each other can predict the success of immunotherapy in patients with colorectal cancer. This spatial analysis may help select patients most likely to benefit from treatment, improving outcomes and minimizing unnecessary treatments.
A new study found that antibiotics promote the growth of antibiotic-resistant bacteria in the gut by providing extra nutrients, allowing these 'bad' bacteria to multiply. The research suggests that targeting beneficial bacteria can help restrict the growth of resistant bacteria, paving the way for microbiome therapeutics treatments.
A study by Texas A&M University found that pregaming is linked to unsafe alcohol use and other risky behaviors among college students. Pregaming was associated with a two-day increase in alcohol use frequency and was found to be around 2.5 times more likely to lead to cannabis or other drug use.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Imperial researchers have imaged Piezo1 channels in human cells and organs, revealing their role in regulating blood pressure, respiration, bladder control, and the immune system. This breakthrough could lead to a better understanding of their role in fundamental physiological processes and potentially new drug targets for diseases.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers identified a new approach to treat poxviruses by targeting a cellular protein, making the virus more susceptible to natural defences. Existing immunosuppressive drugs can restrict replication and spread of poxviruses.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Research reveals that high blood pressure disrupts artery cell messaging, causing arteries to remain constricted and limiting blood flow to the brain. The study provides a potential route for developing first-ever drug treatments for vascular dementia.
Researchers have developed novel liquid metal nanoparticles that combine photothermal therapy with immunotherapy, demonstrating high specificity and low side effects. The nanoparticles can target and destroy cancer cells while also stimulating the immune system to fight against tumors.
Researchers propose GABA-modulating treatments as potential therapeutic targets for depression's cognitive and affective symptoms. The study highlights the importance of GABA-A receptors in regulating balance and signals between neurons, and suggests compounds that promote or inhibit these receptors may alleviate depressive symptoms.
Researchers have identified a novel therapeutic target for pelvic pain in endometriosis by focusing on the IL-1β pathway and its regulation via the JNK signaling pathway. This study suggests that JNK inhibitors may be effective in reducing neuroinflammation and alleviating symptoms of endometriosis-associated pain.
A new study from the University of Missouri found that poverty, low health literacy, cultural beliefs, lack of infrastructure, and political issues hinder diabetes self-management for Haitian migrants. The researchers suggest targeted interventions, such as community gardens and healthcare education through local priests.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
The American Heart Association and the American College of Cardiology recommend a heart-healthy diet and lifestyle to prevent worsening health in people with chronic coronary disease. Clinicians should coordinate care between cardiovascular and primary care professionals, emphasizing team-based approach and social determinants of health.
Researchers from Osaka University found that RNase treatments can either enhance or weaken immune activation in systemic autoimmune diseases. The study suggests that the composition of immune complexes plays a crucial role in determining the effectiveness of RNase treatment.
Researchers from Osaka University identified ten blood proteins associated with mortality in severe burns, including HBA1, TTR, and SERPINF2. These proteins may serve as targets for developing new treatment methods for burns, offering a promising direction for future research.
A study reveals high levels of insecticide resistance among Aedes aegypti populations in Dhaka, compromising mosquito control and increasing dengue burden. Researchers recommend non-insecticidal approaches, such as Wolbachia-infected mosquitoes, to effectively manage dengue vectors.
Researchers at UCLA Jonsson Comprehensive Cancer Center confirmed genetic variants of unknown significance are verified mutations that increase the risk of kidney cancer. The findings could lead to new treatment options for people with hereditary leiomyomatosis and renal cell cancer (HLRCC).
Mass General Cancer Center researchers have pinpointed the APOBEC3A protein as a primary driver of drug resistance in non-small-cell lung cancer. The study reveals that this protein causes mutations and accelerates tumor growth, making it a promising target for new therapies.
Researchers at Texas A&M University found that substance use impairs cognitive flexibility by inhibiting specific neurons. Chronic cocaine or alcohol use alters the local inhibitory brain circuit, leading to decreased cognitive flexibility and increased risk of academic deficits and lower quality of life.
Researchers at the University of Virginia Health System have identified a novel mechanism by which hair cells can repair themselves after damage. This breakthrough understanding has the potential to develop new treatments for age-related hearing loss and other conditions.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Research leaders collaborate with organizations and regulators to develop digital tools for Parkinson's clinical trials. The Digital Drug Development Tools initiative accelerates the regulatory endorsement of these tools, enabling more objective and patient-centered measures.
Scientists at Tokyo Institute of Technology identified ApSigma, a nuclear-encoded apicoplast RNA polymerase σ subunit that coordinates gene expression with the life cycle of Plasmodium falciparum and host circadian rhythm. Melatonin is shown to increase apicoplast transcription and expression of the apSig gene.
Researchers aim to identify best practices for increasing viral suppression in low-income populations with HIV. They will examine state AIDS Drug Assistance Programs to understand disparities in care and outcomes.
A new study has identified 16 new locations in the genome linked to immunoglobulin A (IgA) nephropathy, a common kidney disease. The research confirms an earlier hypothesis that the immune system plays a key role in driving the disease and provides potential drug targets for treatment.
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
The FDA has issued a Biomarker Letter of Support for four novel biomarkers identifying drug-induced pancreatic injury. These microRNAs will enhance the detection of acute drug-induced pancreatic injury (DIPI) in phase 1 clinical trials, improving safety and accuracy.
A new study reveals that only one in four adolescent residential treatment centers across the US provides buprenorphine, a proven tool in fighting opioid addiction. The lack of access to this medication undercuts US efforts to alleviate the overdose epidemic, which claimed over 109,000 lives in 2022.
Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.